Alimera Sciences up on completing enrollment in study of lead therapy

Alimera Sciences

24/05/2023 17:15

** Shares of Alimera Sciences Inc  ALIM.O  up 4.3% at $2.45
    ** Co completes enrollment for study to generate data on
co's lead therapy Iluvien in patients diagnosed with diabetic
macular edema (DME)
    ** DME is the leading cause of blindness in younger and
middle-aged adults
    ** The trial will follow 300 patients over time and collect
data about them as their characteristics or circumstances change
    ** Therapy is already approved in the U.S., Canada, Kuwait,
Lebanon and the UAE to treat DME in certain patient populations
    ** Stock down 9.6% YTD

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))